Trial design
fever
MAY
This was an open-label, randomized, pilot phase 2 clinical trial conducted at five institutions in Japan. We randomized 100 patients hospitalized for COVID-19 with fever greater than or equal to 37.5°C to teprenone and no-teprenone groups in a 1:1 ratio using an online randomization system (the Internet Data and Information system for Clinical and Epidemiological research, a cloud version of the University Medical Information Network [UMIN]). This study was approved by the Certified Review Board of Okayama University (CRB20-001) and was registered at the Japan Registry of Clinical Trials (jRCTs061200002) on May 20, 2020. The study was conducted in compliance with the principles of the Declaration of Helsinki and informed consent was obtained from all patients before any screening procedure or inclusion. Participants were recruited from July 15, 2020, to August 18, 2021. Each patient was followed-up for 10 days or until discharge.